The dynamics of the liver cancer market are anticipated to change in the coming years in the 7MM owing to the improvement in the rise in the number of healthcare spending across the world. In addition, the anticipated launch of emerging therapies will also boost the liver cancer market in the coming years.
LAS VEGAS, June 29, 2023 /PRNewswire/ -- DelveInsight's Liver Cancer Market Insights report includes a comprehensive understanding of current treatment practices, liver cancer emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Liver Cancer Market Report
- As per DelveInsight analysis, the liver cancer market is expected to grow positively at a significant CAGR during the study period (2019-2032).
- According to the Global Cancer Observatory, in the 7MM the ASR incident rate of liver cancer is 7.4/100,000 which is estimated to be around 135,530 new cases in 2020 and the ASR mortality rate of liver cancer is 4.8/100,000 which is estimated to be around 100,790 number of deaths in 2020.
- Leading liver cancer companies such as CStone Pharmaceuticals, SOTIO, Akeso Biopharma, GlaxoSmithKline, Pfizer, Eureka Therapeutics Inc., TriSalus Life Sciences, Inc., Tvardi Therapeutics, Incorporated, Provectus Pharmaceuticals, Qurient Co., Ltd., Merck Sharp & Dohme LLC, Boehringer Ingelheim, DNAtrix, Inc., Omega Therapeutics, Celldex Therapeutics, Lantheus Medical Imaging, Eisai Inc., Codiak BioSciences, Genentech, Inc., Coherus Biosciences, Inc., Fusion Pharmaceuticals Inc., Takeda, and others are developing novel liver cancer drugs that can be available in the liver cancer market in the coming years.
- Some key therapies for liver cancer treatment include Nofazinlimab, Nanrilkefusp Alfa, Ivonescimab, TSR-022, PD-0332991, ET140203, SD-101, TTI-101, PV-10, Q702, BI 765063, DNX-2440, OTX-2002, CDX-527, Piflufolastat F18, E7386, CDK-004, Bevacizumab, CHS-006, FPI-1966, TAK-500, and others.
- The emerging liver cancer therapies are in the mid-phase of their clinical trials and are awaiting a launch to make the pipeline robust.
Discover which therapies are expected to grab the major liver cancer market share @ Liver Cancer Market Report
Liver Cancer Overview
Liver cancer is a form of cancer that begins in the liver. It is the sixth most prevalent type of cancer diagnosed worldwide and the third leading cause of cancer death. The two most common histological subtypes of primary liver cancer are hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). They differ in their etiology and epidemiology. Liver cancer symptoms may be absent or difficult to detect. If the liver cancer begins in the liver (primary liver cancer) or spreads from another region of the body (secondary liver cancer), the symptoms are the same. Gynecomastia, erythrocytosis, elevated cholesterol, hypercalcemia, and hypoglycemia are all liver cancer symptoms.
Only a small percentage of liver cancers are discovered at an advanced stage where these treatments are effective. The majority of people are diagnosed after the cancer has progressed too far to be removed or eradicated. Treatments such as chemotherapy will be used in these circumstances to halt the progression of cancer and relieve symptoms such as pain and discomfort.
Liver Cancer Epidemiology Segmentation
According to the Global cancer observatory, in Japan, the ASR incident rate of liver cancer is 10.4/100,000 which is estimated to be around 45,660 new cases diagnosed in 2020 and the ASR mortality rate of liver cancer is 4.8/100,000 which is estimated to be around 28,155 number of deaths in 2020.
The liver cancer market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
- Liver Cancer Incident Cases
- Liver Cancer Gender-specific Diagnosed Incidence
- Liver Cancer Stage-specific Diagnosed Incidence
- Liver Cancer Treated Cases
Liver Cancer Treatment Market
The optimal management of hepatocellular carcinoma is determined by a number of factors, including tumor size, number, and distribution (unilobar vs. bilobar), tumor relationship to hepatic vasculature, the status of distant metastases, the severity of liver disease, the patient's suitability for liver transplantation, the patient's functional status, and local expertise. The average survival time for symptomatic patients with hepatocellular carcinoma is about 2-3 months. The tumor's size doubles every 2-3 months. Optimal management should aim to extend life without sacrificing quality of life.
Many liver cancer treatment options are available, including surgery, radiation therapy, and immunotherapy. The best approach may be determined by the extent of liver damage caused by cancer or other disease, as well as if cancer has migrated elsewhere in the body, among other criteria. Surgery, ablation, embolization treatment, radiation therapy, immunotherapy, chemotherapy, targeted medication therapy, clinical trials, and gastrointestinal procedures are all alternatives for treating liver cancer.
Several FDA-approved immunotherapy treatments for liver cancer are currently available. Several alternative immunotherapies, such as oncolytic viruses and adoptive cell treatment, are now being investigated in clinical trials. Bevacizumab (AVASTIN), a targeted antibody that targets the VEGF-A pathway, has also been approved as a first-line treatment for subgroups of patients with advanced liver cancer in combination with atezolizumab.
To know more about liver cancer treatment, visit @ Liver Cancer Treatment Drugs
Key Liver Cancer Therapies and Companies
- Nofazinlimab: CStone Pharmaceuticals
- Nanrilkefusp Alfa: SOTIO
- Ivonescimab: Akeso Biopharma
- TSR-022: GlaxoSmithKline
- PD-0332991: Pfizer
- ET140203: Eureka Therapeutics Inc.
- SD-101: TriSalus Life Sciences, Inc.
- TTI-101: Tvardi Therapeutics, Incorporated
- PV-10: Provectus Pharmaceuticals
- Q702: Qurient Co., Ltd./Merck Sharp & Dohme LLC
- BI 765063: Boehringer Ingelheim
- DNX-2440: DNAtrix, Inc.
- OTX-2002: Omega Therapeutics
- CDX-527: Celldex Therapeutics
- Piflufolastat F18: Lantheus Medical Imaging
- E7386: Eisai Inc.
- CDK-004: Codiak BioSciences
- Bevacizumab: Genentech, Inc.
- CHS-006: Coherus Biosciences, Inc.
- FPI-1966: Fusion Pharmaceuticals Inc.
- TAK-500: Takeda
Learn more about the FDA-approved drugs for liver cancer @ Drugs for Liver Cancer Treatment
Liver Cancer Market Dynamics
The dynamics of the liver cancer market are expected to change in the coming years. Increasing incidence due to changes in lifestyle, increased obesity, and others will drive the liver cancer market forward. In addition, increased awareness as a result of initiatives to educate people about diseases is crucial which will propel the liver cancer market growth. Moreover, the presence of a strong pipeline is projected to bring about a beneficial impact on the liver cancer market.
As the liver cancer pipeline is very robust; many potential therapies are being investigated for the treatment of liver cancer, and it is safe to predict that the treatment space will significantly impact the liver cancer market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate are expected to drive the growth of the liver cancer market in the 7MM.
However, several factors are impeding the growth of the liver cancer market. Choosing the best treatments from an ever-changing landscape has been difficult, particularly in later therapy settings. Moreover, the availability of generics may have an adverse influence on the liver cancer market. Furthermore, the liver cancer market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the liver cancer market growth.
Report Metrics | Details |
Study Period | 2019-2032 |
Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Base Year | 2019 |
Key Liver Cancer Companies | CStone Pharmaceuticals, SOTIO, Akeso Biopharma, GlaxoSmithKline, Pfizer, Eureka Therapeutics Inc., TriSalus Life Sciences, Inc., Tvardi Therapeutics, Incorporated, Provectus Pharmaceuticals, Qurient Co., Ltd., Merck Sharp & Dohme LLC, Boehringer Ingelheim, DNAtrix, Inc., Omega Therapeutics, Celldex Therapeutics, Lantheus Medical Imaging, Eisai Inc., Codiak BioSciences, Genentech, Inc., Coherus Biosciences, Inc., Fusion Pharmaceuticals Inc., Takeda, and others |
Key Liver Cancer Therapies | Nofazinlimab, Nanrilkefusp Alfa, Ivonescimab, TSR-022, PD-0332991, ET140203, SD-101, TTI-101, PV-10, Q702, BI 765063, DNX-2440, OTX-2002, CDX-527, Piflufolastat F18, E7386, CDK-004, Bevacizumab, CHS-006, FPI-1966, TAK-500, and others |
Scope of the Liver Cancer Market Report
- Therapeutic Assessment: Liver Cancer current marketed and emerging therapies
- Liver Cancer Market Dynamics: Attribute Analysis of Emerging Liver Cancer Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Liver Cancer Market Access and Reimbursement
Discover more about liver cancer drugs in development @ Liver Cancer Clinical Trials
Table of Contents
1. | Liver Cancer Market Key Insights |
2. | Liver Cancer Market Report Introduction |
3. | Liver Cancer Market Overview at a Glance |
4. | Liver Cancer Market Executive Summary |
5. | Disease Background and Overview |
6. | Liver Cancer Treatment and Management |
7. | Liver Cancer Epidemiology and Patient Population |
8. | Patient Journey |
9. | Liver Cancer Marketed Drugs |
10. | Liver Cancer Emerging Drugs |
11. | Seven Major Liver Cancer Market Analysis |
12. | Liver Cancer Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Unmet Needs |
16. | SWOT Analysis |
17. | Appendix |
18. | DelveInsight Capabilities |
19. | Disclaimer |
20. | About DelveInsight |
Related Reports
Liver Cancer Epidemiology Forecast
Liver Cancer Epidemiology Forecast - 2032 report delivers an in-depth understanding of the disease, historical and forecasted liver cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Liver Cancer Pipeline
Liver Cancer Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key liver cancer companies, including Shanghai Henlius Biotech, Boehringer Ingelheim, Bristol-Myers Squibb, Jiangsu Hengrui Medicine, Glaxo SmithKline, ZAI Lab, Beijing Immunochina Medical Science and Technology, among others.
Advanced Liver Cancer Pipeline
Advanced Liver Cancer Pipeline Insight - 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced liver cancer companies, including Genoscience, Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, among others.
Advanced Liver Cancer Market
Advanced Liver Cancer Market Insights, Epidemiology, and Market Forecast - 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced liver cancer companies, including Genoscience, Eureka Therapeutics, Celsion Corporation, H3 Biomedicine, TriSalus Life Sciences, Celldex Therapeutics, Takeda, Megapro Biomedical Company, Polaris Group, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo
View original content:https://www.prnewswire.co.uk/news-releases/liver-cancer-market-to-proliferate-positively-assesses-delveinsight--key-companies-active-in-the-domain---sotio-glaxosmithkline-pfizer-merck-takeda-genentech-boehringer-ingelheim-dnatrix-celldex-301867063.html
